These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 8229782

  • 1. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.
    Müller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtmann R, Perzborn E, Beckermann B, Bühner K, Ahr HJ, Mohrs KH.
    J Pharmacol Exp Ther; 1993 Oct; 267(1):51-7. PubMed ID: 8229782
    [Abstract] [Full Text] [Related]

  • 2. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics.
    Müller-Peddinghaus R, Fruchtmann R, Ahr HJ, Beckermann B, Bühner K, Fugmann B, Junge B, Matzke M, Kohlsdorfer C, Raddatz S.
    J Lipid Mediat; 1993 Oct; 6(1-3):245-8. PubMed ID: 8395246
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis.
    Fruchtmann R, Mohrs KH, Hatzelmann A, Raddatz S, Fugmann B, Junge B, Horstmann H, Müller-Peddinghaus R.
    Agents Actions; 1993 Mar; 38(3-4):188-95. PubMed ID: 8213345
    [Abstract] [Full Text] [Related]

  • 7. Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test.
    Burchardt ER, Müller-Peddinghaus R.
    Prostaglandins Leukot Essent Fatty Acids; 1997 Apr; 56(4):301-6. PubMed ID: 9150376
    [Abstract] [Full Text] [Related]

  • 8. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC.
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
    Lorrain DS, Bain G, Correa LD, Chapman C, Broadhead AR, Santini AM, Prodanovich P, Darlington JV, Hutchinson JH, King C, Lee C, Baccei C, Li Y, Arruda JM, Evans JF.
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of a novel leukotoriene synthesis inhibitor, BAY x1005, on the antigen-and LPS-induced airway hyperresponsiveness in guinea pigs.
    Nagai H, Takeda H, Uno T, Tanaka H, Matsuo A.
    Prostaglandins; 1996 Feb; 51(2):139-48. PubMed ID: 8711135
    [Abstract] [Full Text] [Related]

  • 15. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
    Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R.
    Biochem Pharmacol; 1993 Jan 07; 45(1):101-11. PubMed ID: 8381000
    [Abstract] [Full Text] [Related]

  • 16. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug 07; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 17. Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)-benzo (b)thiophene-2-carboxamide.
    Bailey PJ, Dallob AL, Allison DL, Anderson RL, Bach T, Durette PL, Hand KM, Hopple SL, Luell S, Meurer R.
    Arzneimittelforschung; 1988 Mar 07; 38(3):372-8. PubMed ID: 3132928
    [Abstract] [Full Text] [Related]

  • 18. A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats.
    Böttcher I, Schweizer A, Glatt M, Werner H.
    Drugs Exp Clin Res; 1987 Mar 07; 13(5):237-45. PubMed ID: 3500026
    [Abstract] [Full Text] [Related]

  • 19. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM, Fraisse L, Bachy A, Valette G, Savi P, Laplace MC, Lassalle J, Roche B, Lale A, Keane PE.
    J Lipid Mediat; 1993 Aug 07; 8(1):31-51. PubMed ID: 8257776
    [Abstract] [Full Text] [Related]

  • 20. Effect of a 5-lipoxygenase inhibitor on nerve growth factor-induced thermal hyperalgesia in the rat.
    Amann R, Schuligoi R, Lanz I, Peskar BA.
    Eur J Pharmacol; 1996 Jun 13; 306(1-3):89-91. PubMed ID: 8813619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.